2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)
The estimated number of patients requiring dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and an oral inhibitor of the platelet P2Y12 receptor for adenosine 5'-diphosphate (ADP), is considerable and has increased over time in Europe. Based on population estimates from 2015, in the region of 1 400 000 and 2 200 000 patients per year may have an indication for DAPT after coronary intervention or myocardial infarction (MI), respectively. [...]
There is, however, confusion in the community around the optimal type and duration of DAPT in patients with established coronary artery disease (CAD), undergoing coronary revascularization or not.4 This derives from apparently conflicting results arising from the available studies and limited evidence on various patient subsets (e.g. elderly patients, with comorbidities or at greater bleeding risk) in whom the trade-off between the benefits and risks of DAPT may differ from those observed in more selected patient cohorts included in trials. Therefore, the scope of this focused update is to address recommendations on DAPT in patients with CAD.
Read full Guideline